These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33051199)

  • 21. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series.
    Nagao A; Bingo M; Yamaguchi T; Fukutake K
    Cureus; 2023 Jan; 15(1):e33573. PubMed ID: 36779089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
    Iorio A; Fischer K; Blanchette V; Rangarajan S; Young G; Morfini M;
    Thromb Haemost; 2017 Jun; 117(6):1023-1030. PubMed ID: 28357444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
    Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
    Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2016 May; 141 Suppl 3():S5-8. PubMed ID: 27288064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.
    Pasca S; Zanon E
    Drug Des Devel Ther; 2022; 16():3109-3116. PubMed ID: 36132333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Half-life extension through albumin fusion technologies.
    Schulte S
    Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
    Santagostino E; Martinowitz U; Lissitchkov T; Pan-Petesch B; Hanabusa H; Oldenburg J; Boggio L; Negrier C; Pabinger I; von Depka Prondzinski M; Altisent C; Castaman G; Yamamoto K; Álvarez-Roman MT; Voigt C; Blackman N; Jacobs I;
    Blood; 2016 Apr; 127(14):1761-9. PubMed ID: 26755710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice?
    Farid S; Sewaralthahab S; Smith HP
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
    Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J; Bevan D; Sorensen B; Rangarajan S
    J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
    Koopman SF; Goedhart TMHJ; Bukkems LH; Mulders TM; Leebeek FWG; Fijnvandraat K; Coppens M; Mathias M; Collins PW; Tait RC; Bagot CN; Curry N; Payne J; Chowdary P; Cnossen MH; Mathôt RAA;
    Br J Clin Pharmacol; 2024 Jan; 90(1):220-231. PubMed ID: 37567779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
    Tardy B; Lambert T; Chamouni P; Montmartin A; Trossaert M; Claeyssens S; Berger C; Ardillon L; Gay V; Delavenne X; Harroche A; Chelle P
    Haemophilia; 2022 Jul; 28(4):542-547. PubMed ID: 35420242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.